Get started
CureVac N.V.CureVac N.V.CureVac N.V.

CureVac N.V.

No trades
See on Supercharts
OverviewFinancialsNewsDiscussionsTechnicalsForecastSeasonalsETFs

5CV chart


Full chart

5CV upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪959.78 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
5.972
Basic EPS (TTM)
0.804 CHF
Net income (FY)
‪159.33 M‬ CHF
Revenue (FY)
‪525.76 M‬ CHF
Shares float
‪95.50 M‬
Beta (1Y)
1.17

Employees


Employees (FY)
983
Change (1Y)
−189 −16.13%
Revenue / Employee (1Y)
‪534.85 K‬ CHF
Net income / Employee (1Y)
‪162.09 K‬ CHF

About CureVac N.V.


Sector
Health Technology
Industry
Biotechnology
CEO
Alexander Zehnder
Website
curevac.com
Headquarters
Tübingen
Founded
2020
ISIN
NL0015436031
FIGI
BBG00WRCCGP7
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Check out other big names from the same industry as 5CV.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

5CV news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 5CV is 4.268 CHF — it has decreased by −0.30% in the past 24 hours. Watch CureVac N.V. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange CureVac N.V. stocks are traded under the ticker 5CV.
5CV stock has risen by 1.33% compared to the previous week, the month change is a −1.07% fall, over the last year CureVac N.V. has showed a 54.25% increase.
We've gathered analysts' opinions on CureVac N.V. future price: according to them, 5CV price has a max estimate of 4.43 CHF and a min estimate of 4.33 CHF. Watch 5CV chart and read a more detailed CureVac N.V. stock forecast: see what analysts think of CureVac N.V. and suggest that you do with its stocks.
5CV reached its all-time high on Aug 26, 2021 with the price of 68.847 CHF, and its all-time low was 2.095 CHF and was reached on Apr 29, 2024. View more price dynamics on 5CV chart.
See other stocks reaching their highest and lowest prices.
5CV stock is 0.73% volatile and has beta coefficient of 1.17. Track CureVac N.V. stock price on the chart and check out the list of the most volatile stocks — is CureVac N.V. there?
Today CureVac N.V. has the market capitalization of ‪959.78 M‬, it has decreased by −1.47% over the last week.
Yes, you can track CureVac N.V. financials in yearly and quarterly reports right on TradingView.
CureVac N.V. is going to release the next earnings report on Nov 18, 2025. Keep track of upcoming events with our Earnings Calendar.
5CV earnings for the last quarter are −0.14 CHF per share, whereas the estimation was −0.17 CHF resulting in a 17.50% surprise. The estimated earnings for the next quarter are 0.09 CHF per share. See more details about CureVac N.V. earnings.
CureVac N.V. revenue for the last quarter amounts to ‪11.96 M‬ CHF, despite the estimated figure of ‪3.12 M‬ CHF. In the next quarter, revenue is expected to reach ‪64.57 M‬ CHF.
5CV net income for the last quarter is ‪−48.53 M‬ CHF, while the quarter before that showed ‪−31.74 M‬ CHF of net income which accounts for −52.90% change. Track more CureVac N.V. financial stats to get the full picture.
No, 5CV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 26, 2025, the company has 983 employees. See our rating of the largest employees — is CureVac N.V. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CureVac N.V. EBITDA is ‪244.57 M‬ CHF, and current EBITDA margin is 42.00%. See more stats in CureVac N.V. financial statements.
Like other stocks, 5CV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CureVac N.V. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CureVac N.V. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CureVac N.V. stock shows the sell signal. See more of CureVac N.V. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.